AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative

Related Keywords

Macau ,China ,South Korea ,Shanghai ,Singapore ,Vijay Karwal ,Ocular Therapeutix Inc ,Nasdaq ,Singapore Health Sciences Authority ,Affamed Therapeutics ,New Drug Application ,Chief Executive Officer ,Mainland China ,Ocular Therapeutix ,Greater China ,Amed Therapeutics ,